RTP Mobile Logo
Proceedings from the First Annual Miami General Medical Oncology Symposium
Released April 2019

Proceedings from a weekend-long symposium featuring discussion of significant new data sets, promising treatment strategies and key interdisciplinary management considerations in the care of patients with breast, lung, gastrointestinal, genitourinary, dermatologic, ovarian and select hematologic cancers. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows and other allied cancer professionals.

    OVERVIEW OF ACTIVITY
    The fact that community-based general medical oncologists are responsible for the management of such a breadth of diseases clearly establishes them as a unique entity and supports the mandate that, whether they are exposed to 1 patient with a particular tumor type throughout the year or 100, they must be properly equipped to deliver high-quality, state-of-the-art care for every case.

    Unfortunately, this can be a highly daunting task for many reasons, including simple lack of exposure to specific diseases and the often complex diagnostic and therapeutic algorithms that accompany clinical management. Although it is clear that many practical and logistical factors affect oncologists’ ability to stay abreast of notable clinical advances and to deliver optimal care, it is important to recognize that unprecedented progress in cancer research is playing a critical role. Fueled by an increased understanding of the biologic underpinnings of tumor development and progression, clinical research platforms largely focused on evaluating the potential benefits of novel targeted therapeutics and immunotherapies possessing unique mechanisms of action and safety profiles have led to improved outcomes in myriad large and rigorous clinical trials across many different tumor types. The successes yielded have provided medical oncologists and patients with many beneficial FDA-endorsed options, but the availability of so many new treatments in such a short period, coupled with the fact that many are indicated for less commonly occurring diseases, represents a particularly challenging situation for those practicing in the community.

    To bridge this gap, these proceedings from a weekend-long symposium feature discussion of significant new data sets, promising treatment strategies and key interdisciplinary management considerations in the care of patients with breast, lung, gastrointestinal, genitourinary, dermatologic, ovarian and select hematologic cancers. By providing access to the perspectives of tumor type-specific experts from a variety of fields, this activity aims to ensure that those involved in the management of these diseases are empowered to deliver best-practice patient care.

    LEARNING OBJECTIVES

    • Effectively apply the results of practice-changing clinical research to the care of patients with breast, lung, gastrointestinal, genitourinary, dermatologic, ovarian and select hematologic cancers.
    • Appraise the clinical relevance of recent pivotal cancer research results published in peer-reviewed journals and/or presented at major oncology conferences.
    • Recall ongoing trials in breast, lung, gastrointestinal, genitourinary, dermatologic, ovarian and select hematologic cancers, and refer appropriate patients for study participation.
    • Use an understanding of tumor biomarkers and single and multigene signatures to individualize the care of patients with cancer.
    • Educate patients with diverse hematologic cancers and solid tumors about the benefits and risks of new therapeutic agents and strategies.
    • Refine or validate existing cancer-specific treatment algorithms based on exposure to new data sets and the perspectives of tumor-specific clinical investigators.
    • Evaluate the mechanisms of action, tolerability and efficacy of promising investigational agents, and consider their potential implications for clinical practice.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Research To Practice designates this enduring material for a maximum of 13.25 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 13.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for this activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, this program has been specifically designed for the following ABIM specialty: medical oncology and hematology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/GMO19/CME.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Harold J Burstein, MD, PhD
    Associate Professor of Medicine
    Harvard Medical School
    Breast Oncology Center
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    No relevant conflicts of interest to disclose.

    Robert L Coleman, MD
    Professor and Executive Director, Cancer Network Research
    Anne Rife Cox Chair in Gynecology
    Department of Gynecologic Oncology and Reproductive Medicine
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Advisory Committee and Contracted Research: AbbVie Inc, Array BioPharma Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, GamaMabs Pharma, Genentech, Genmab, ImmunoGen Inc, Janssen Biotech Inc, Merck, Novartis, Tesaro; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP.

    Adil Daud, MD
    Director, Melanoma Program
    Clinical Professor of Medicine
    University of California, San Francisco
    San Francisco, California

    Advisory Committee: Bristol-Myers Squibb Company, Merck, Novartis, OncoSec Medical, Pfizer Inc; Contracted Research: Bristol-Myers Squibb Company, GlaxoSmithKline, Merck, OncoSec Medical, Pfizer Inc; Ownership Interest: OncoSec Medical.

    Matthew S Davids, MD, MMSc
    Assistant Professor of Medicine, Harvard Medical School
    Director, DFCI Lymphoma BioBank
    Associate Director, CLL Center
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    Advisory Committee: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, AstraZeneca Pharmaceuticals LP, Genentech, Gilead Sciences Inc, Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company, TG Therapeutics Inc; Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech, Janssen Biotech Inc, MEI Pharma Inc, Merck, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, Syros Pharmaceuticals Inc, Verastem Inc; Contracted Research: Acerta Pharma — A member of the AstraZeneca Group, Bristol-Myers Squibb Company, Genentech, MEI Pharma Inc, Pharmacyclics LLC, an AbbVie Company, Surface Oncology, TG Therapeutics Inc, Verastem Inc.

    Anthony El-Khoueiry, MD
    Associate Professor of Clinical Medicine
    Medical Director of Clinical Investigations Support Office
    Phase I Program Director
    USC Norris Comprehensive Cancer Center
    Los Angeles, California

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, CytomX Therapeutics, Eisai Inc, EMD Serono Inc, Exelixis Inc, Merck, Pieris Pharmaceuticals Inc; Consulting Agreements: Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company; Contracted Research: Astex Pharmaceuticals, AstraZeneca Pharmaceuticals LP.

    Peter C Enzinger, MD
    Director, Center for Esophageal and Gastric Cancer
    Associate Professor of Medicine, Harvard Medical School
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    Consulting Agreements: Astellas Pharma Global Development Inc, Celgene Corporation, Lilly, Loxo Oncology, Merck, Taiho Oncology Inc.

    Charles S Fuchs, MD, MPH
    Richard Sackler and Jonathan Sackler Professor of Medicine (Medical Oncology)
    Director, Yale Cancer Center
    Physician-in-Chief
    Smilow Cancer Hospital at Yale New Haven
    New Haven, Connecticut

    Advisory Committee: CytomX Therapeutics; Consulting Agreements: Agios Pharmaceuticals Inc, Bain Capital, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Dicerna Pharmaceuticals Inc, Entrinsic Health Solutions Inc, Five Prime Therapeutics Inc, Genentech, Gilead Sciences Inc, KEW Group LLC, Lilly, Merck, Merrimack Pharmaceuticals Inc, Pfizer Inc, Roche Laboratories Inc, Sanofi Genzyme, Taiho Oncology Inc, Unum Therapeutics.

    Tim Greten, MD
    Bethesda, Maryland

    No relevant conflicts of interest to disclose.

    Matthew Gubens, MD, MS
    Associate Professor, Thoracic Medical Oncology
    University of California, San Francisco
    San Francisco, California

    Consulting Agreements: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Genentech, Heron Therapeutics Inc, Roche Laboratories Inc, Takeda Oncology; Contracted Research: Celgene Corporation, Merck, Novartis, OncoMed Pharmaceuticals Inc, Roche Laboratories Inc.

    Maha Hussain, MD
    Genevieve Teuton Professor of Medicine
    Division of Hematology/Oncology
    Deputy Director
    Robert H Lurie Comprehensive Cancer Center
    Northwestern University Feinberg School of Medicine
    Chicago, Illinois

    Advisory Committee: AstraZeneca Pharmaceuticals LP; Consulting Agreements: Genentech, Pfizer Inc, Sanofi Genzyme; Contracted Research: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Genentech, Pfizer Inc.

    Nitin Jain, MD
    Associate Professor of Medicine
    Department of Leukemia
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Advisory Committee and Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies, AstraZeneca Pharmaceuticals LP, Janssen Biotech Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company; Contracted Research: AbbVie Inc, Adaptive Biotechnologies, ADC Therapeutics SA, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Cellectis, Genentech, Incyte Corporation, Janssen Biotech Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Servier; Data and Safety Monitoring Board/Committee: Janssen Biotech Inc.

    Jonathan L Kaufman, MD
    Associate Professor of Hematology and Medical Oncology
    Winship Cancer Institute of Emory University
    Atlanta, Georgia

    Consulting Agreements: Bristol-Myers Squibb Company, Celgene Corporation, Janssen Biotech Inc, Takeda Oncology; Data and Safety Monitoring Board/Committee: Incyte Corporation, Karyopharm Therapeutics, TG Therapeutics Inc.

    Andrew H Ko, MD
    Professor and Interim Chief (Oncology)
    Department of Medicine (Hematology/Oncology)
    University of California, San Francisco
    Helen Diller Family Comprehensive Cancer Center
    San Francisco, California

    Advisory Committee: ARMO Biosciences, a wholly owned subsidiary of Eli Lilly and Company, Celgene Corporation, Rafael Pharmaceuticals Inc; Consulting Agreement: Pharmacyclics LLC, an AbbVie Company; Contracted Research: AbGenomics International Inc, Apexigen, Astellas Pharma Global Development Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, Halozyme Inc, Merck, Merrimack Pharmaceuticals Inc.

    John P Leonard, MD
    Richard T Silver Distinguished Professor of Hematology and Medical Oncology
    Associate Dean for Clinical Research
    Associate Director, Sandra and Edward Meyer Cancer Center
    Executive Vice Chair, Joan and Sanford I Weill Department of Medicine
    Weill Cornell Medicine
    New York, New York

    Consulting Agreements: ADC Therapeutics SA, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene, Celgene Corporation, Genentech, Gilead Sciences Inc, Karyopharm Therapeutics, MEI Pharma Inc, MorphoSys, Nordic Nanovector, Novartis, Roche Laboratories Inc, Sutro Biopharma Inc; Data and Safety Monitoring Board/Committee: Biotest Pharmaceuticals Corporation, Bristol-Myers Squibb Company.

    Evan J Lipson, MD
    Associate Professor, Medical Oncology
    Johns Hopkins University School of Medicine
    Bloomberg-Kimmel Institute for Cancer Immunotherapy
    The Sidney Kimmel Comprehensive Cancer Center
    Baltimore, Maryland

    Advisory Committee: Bristol-Myers Squibb Company; Consulting Agreements: Array BioPharma Inc, Bristol-Myers Squibb Company, EMD Serono Inc, MacroGenics Inc, Merck, Novartis, Takeda Oncology; Contracted Research: Bristol-Myers Squibb Company, Merck, Sysmex Corporation.

    Ursula Matulonis, MD
    Chief, Division of Gynecologic Oncology
    Brock-Wilson Family Chair
    Dana-Farber Cancer Institute
    Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Advisory Committee: 2X Oncology, FUJIFILM Pharmaceuticals USA Inc, Geneos Therapeutics, ImmunoGen Inc, Mersana Therapeutics; Consulting Agreement: Merck; Data and Safety Monitoring Board/Committee: Advaxis Inc.

    Craig Moskowitz, MD
    Physician in Chief, Oncology Service Line, Sylvester Comprehensive Cancer Center
    Professor of Medicine, Miller School of Medicine, University of Miami Health System
    Don Soffer Clinical Research Center
    Miami, Florida

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Karyopharm Therapeutics, Merck, Seattle Genetics, Takeda Oncology, Vaniam Group; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Karyopharm Therapeutics, Merck, Seattle Genetics, Takeda Oncology, Vaniam Group; Contracted Research: Merck, Seattle Genetics.

    Joel W Neal, MD, PhD
    Assistant Professor of Medicine
    Division of Oncology
    Stanford Cancer Institute
    Stanford University
    Stanford, California

    Advisory Committee and Consulting Agreements: Ariad Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Exelixis Inc, Genentech, Jounce Therapeutics Inc, Lilly, Loxo Oncology, Roche Laboratories Inc, Takeda Oncology; Contracted Research: Ariad Pharmaceuticals Inc, Boehringer Ingelheim Pharmaceuticals Inc, Exelixis Inc, Genentech, Merck, Nektar, Novartis, Roche Laboratories Inc, Takeda Oncology.

    Sattva S Neelapu, MD
    Professor and Deputy Chair ad interim
    Department of Lymphoma and Myeloma
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Advisory Committee and Consulting Agreements: Celgene Corporation, Gilead Sciences Inc, Kite Pharma Inc, Merck, Novartis, Pfizer Inc, Unum Therapeutics; Contracted Research: Bristol-Myers Squibb Company, Cellectis, Gilead Sciences Inc, Karus Therapeutics, Kite Pharma Inc, Merck, Poseida Therapeutics Inc.

    Joyce O’Shaughnessy, MD
    Chair, Breast Cancer Research Program
    Baylor Charles A Sammons Cancer Center
    Celebrating Women Chair in Breast Cancer Research
    Texas Oncology
    US Oncology
    Dallas, Texas

    Advisory Committee and Consulting Agreements: Agendia Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Eisai Inc, Genentech, Ipsen Biopharmaceuticals Inc, Lilly, Novartis, Pfizer Inc, Puma Biotechnology Inc, Roche Laboratories Inc, Seattle Genetics; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Lilly, Novartis.

    Geoffrey R Oxnard, MD
    Lowe Center for Thoracic Oncology
    Dana-Farber Cancer Institute
    Assistant Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Consulting Agreements: AstraZeneca Pharmaceuticals LP, DropWorks CEI, GRAIL Inc, Guardant Health, Ignyta Inc, Inivata, Loxo Oncology.

    Philip A Philip, MD, PhD
    Kathryn Cramer Endowed Chair in Cancer Research
    Professor of Oncology and Pharmacology
    Leader, GI and Neuroendocrine Oncology
    Vice President of Medical Affairs
    Karmanos Cancer Institute
    Wayne State University
    Detroit, Michigan

    Advisory Committee: AbbVie Inc, Biolinx, Caris Life Sciences, Celgene Corporation, Eisai Inc, Forty Seven Inc, Halozyme Inc, Ipsen Biopharmaceuticals Inc, Lexicon Pharmaceuticals Inc, Lilly, Merck, Novartis, Rafael Pharmaceuticals Inc, Taiho Oncology Inc; Consulting Agreements: AbbVie Inc, Celgene Corporation, Lilly, Merck, Rafael Pharmaceuticals Inc; Contracted Research: AAA Pharmaceutical, Astellas Pharma Global Development Inc, Bayer HealthCare Pharmaceuticals, Biolinx, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Eisai Inc, Forty Seven Inc, Gilead Sciences Inc, Halozyme Inc, Incyte Corporation, Lilly, Merck, Novocure, QED Therapeutics, Taiho Oncology Inc, Tyme Technologies Inc; Data and Safety Monitoring Board/Committee: ASLAN Pharmaceuticals, Blueprint Medicines, Erytech Pharma, Lexicon Pharmaceuticals Inc; Speakers Bureau: Bristol-Myers Squibb Company, Celgene Corporation, Ipsen Biopharmaceuticals Inc, Merck.

    Elizabeth R Plimack, MD, MS
    Chief, Division of Genitourinary Medical Oncology
    Director, Genitourinary Clinical Research
    Associate Professor, Department of Hematology/Oncology
    Fox Chase Cancer Center, Temple Health
    Philadelphia, Pennsylvania

    Advisory Committee: Bristol-Myers Squibb Company, Genentech, Incyte Corporation, Janssen Biotech Inc, Merck; Contracted Research: Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, Merck, Peloton Therapeutics Inc, Pfizer Inc; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals, Pfizer Inc.

    Daniel A Pollyea, MD, MS
    Associate Professor of Medicine
    Clinical Director of Leukemia Services
    Robert H Allen, MD Chair in Hematology Research
    Division of Hematology
    University of Colorado School of Medicine
    Aurora, Colorado

    Advisory Committee: AbbVie Inc, Astellas Pharma Global Development Inc, Celgene Corporation, Celyad, Daiichi Sankyo Inc, Gilead Sciences Inc, Pfizer Inc; Contracted Research: AbbVie Inc; Data and Safety Monitoring Board/Committee: GlycoMimetics Inc, Tolero Pharmaceuticals Inc.

    David L Porter, MD
    Abramson Cancer Center, University of Pennsylvania Health System
    Jodi Fisher Horowitz Professor of Leukemia Care Excellence
    Director, Blood and Marrow Transplantation
    Philadelphia, Pennsylvania

    Advisory Committee: Humanigen Inc, Incyte Corporation, Kite Pharma Inc, Novartis; Ownership Interest: Genentech, Roche Laboratories Inc; Employment (Spouse): Genentech.

    David I Quinn, MBBS, PhD
    Medical Director, Norris Cancer Hospital and Clinics
    Head, GU Cancer Section
    Division of Cancer Medicine and Blood Diseases
    USC Norris Comprehensive Cancer Center
    Los Angeles, California

    Advisory Committee and Consulting Agreements: Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Dendreon Pharmaceuticals Inc, Exelixis Inc, Genentech, Janssen Biotech Inc, Merck, Novartis, Pfizer Inc, Roche Laboratories Inc, Sanofi Genzyme; Contracted Research: Astellas Pharma Global Development Inc, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Genentech, Merck, Pfizer Inc; Data and Safety Monitoring Board/Committee: Eisai Inc, US Biotest Inc.

    A Oliver Sartor, MD
    CE and Bernadine Laborde Professor for Cancer Research
    Medical Director, Tulane Cancer Center
    Assistant Dean for Oncology
    Tulane Medical School
    New Orleans, Louisiana

    Advisory Committee: Bayer HealthCare Pharmaceuticals, EMD Serono Inc, Fusion Pharmaceuticals; Consulting Agreements: Advanced Accelerator Applications, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Blue Earth Diagnostics, Constellation Pharmaceuticals, Dendreon Pharmaceuticals Inc, EMD Serono Inc, Endocyte Inc, Hinova Pharmaceuticals Inc, Johnson & Johnson Pharmaceuticals, Myovant Sciences, Pfizer Inc, Progenics Pharmaceuticals Inc, Sanofi Genzyme; Contracted Research: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Constellation Pharmaceuticals, Dendreon Pharmaceuticals Inc, Endocyte Inc, Innocrin Pharmaceuticals Inc, Invitae, Johnson & Johnson Pharmaceuticals, Merck, Progenics Pharmaceuticals Inc, Roche Laboratories Inc, Sanofi Genzyme, SOTIO LLC; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, Johnson & Johnson Pharmaceuticals, Myovant Sciences, Pfizer Inc; Ownership Interest: Lilly.

    Lecia V Sequist, MD, MPH
    Director, Center for Innovation in Early Cancer Detection
    Massachusetts General Hospital Cancer Center
    The Landry Family Associate Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Consulting Agreements: AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Genentech, Merrimack Pharmaceuticals Inc, Pfizer Inc; Contracted Research: Boehringer Ingelheim Pharmaceuticals Inc, Genentech, Merrimack Pharmaceuticals Inc, Novartis.

    George W Sledge Jr, MD
    Professor of Medicine
    Chief, Division of Oncology
    Department of Medicine
    Stanford University School of Medicine
    Stanford, California

    Advisory Committee: Symphogen A/S, Synaffix BV, Syndax Pharmaceuticals Inc, Taiho Oncology Inc; Board of Directors: Tessa Therapeutics; Contracted Research: Pfizer Inc; Ownership Interest: Syndax Pharmaceuticals Inc.

    Richard M Stone, MD
    Director, Translational Research, Leukemia Division
    Dana-Farber Cancer Institute
    Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Consulting Agreements: AbbVie Inc, Actinium Pharmaceuticals Inc, Agios Pharmaceuticals Inc, argenx, Arog Pharmaceuticals Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Jazz Pharmaceuticals Inc, MacroGenics Inc, Novartis, Otsuka America Pharmaceutical Inc, Pfizer Inc, Rafael Pharmaceuticals Inc, Stemline Therapeutics Inc, Takeda Oncology; Data and Safety Monitoring Board/Committee: argenx, Celgene Corporation, Takeda Oncology.

    Eric P Winer, MD
    Senior Vice President for Medical Affairs
    Chief, Division of Breast Oncology
    Thompson Chair in Breast Cancer Research
    Dana-Farber Cancer Institute
    Professor of Medicine, Harvard Medical School
    Boston, Massachusetts

    Advisory Committee: Leap Therapeutics Inc; Consulting Agreements: Carrick Therapeutics, Genentech, GlaxoSmithKline, Lilly; Ownership Interest: Verastem Inc.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genmab, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AbbVie Inc, Agios Pharmaceuticals Inc, Array BioPharma Inc, Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Eisai Inc, Exelixis Inc, Genentech, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Merck, Novartis, Pharmacyclics LLC, an AbbVie Company/Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Sanofi Genzyme, Seattle Genetics and Takeda Oncology.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: April 2019
    Expiration date: April 2020

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):

Keynote Session: Chimeric Antigen Receptor (CAR) T-Cell Therapy

Colorectal and Gastric Cancer

Hepatocellular Carcinoma

Melanoma

Chronic Lymphocytic Leukemia (CLL)

Hodgkin and Non-Hodgkin Lymphomas

Ovarian Cancer (OC)

Pancreatic Cancer

ER-Positive, HER2-Negative Breast Cancer (BC)

HER2-Positive and Triple-Negative BC

Acute Myeloid Leukemia

Prostate Cancer (PC)

Renal Cell and Bladder Cancer

Targeted Treatment of Lung Cancer

Immune Checkpoint Inhibitors in Lung Cancer

Select Publications